<DOC>
	<DOCNO>NCT01308489</DOCNO>
	<brief_summary>This randomize clinical trial study minimally invasive surgery treat patient spinal tumor . Posterior spinal tumor resection anterior posterior spinal tumor resection less invasive type surgery spinal tumor may fewer side effect improve recovery</brief_summary>
	<brief_title>Minimally Invasive Surgery Treating Patients With Spinal Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Length operation ( operate room [ OR ] time ) . II . Estimated blood loss ( EBL ) . III . Complication rate . IV . Neurological preservation . SECONDARY OBJECTIVES : I . Motor strength sensory level ( neurological outcome ) . II . Bladder bowel function . III . Post-operative pain . IV . Hospital length stay ( recovery time ) . V. Arthrodesis . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients undergo posterior spinal tumor resection day 0 . ARM II : Patients undergo anterior posterior spinal tumor resection day 0 . After completion study treatment , patient follow 6 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Spinal Cord Neoplasms</mesh_term>
	<criteria>Patients must diagnosis primary , secondary metastatic spine tumor undergo posterior spinal fusion without anterior fusion anywhere occiput sacrum Greater 3 month life expectancy Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry six month follow duration study participation ; woman become pregnant suspect pregnant participate trial , inform treat physician immediately All subject must ability understand willingness sign write informed consent Patients surgical candidate spine tumor removal , determine surgical team Patients undergone previous spine surgery tumor removal exclude Patients renal cell carcinoma As emphasis blood loss length surgery , critical variable homogeneity vascularity tumor ; hypervascular spine tumor regard surgeon amongst challenge case ; far three common hypervascular metastatic tumor arise renal cell carcinoma , thyroid carcinoma melanoma ; pathology usually regard distinct subset reason majority study ; rarely encounter later two pathology practice , choose include former ; however , homogenize study population exclude three know hypervascular metastatic spine tumor Subjects , opinion investigator , may able comply safety monitoring requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>